{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T12:15:08Z","timestamp":1791375308036,"version":"4.3.1"},"reference-count":25,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2024,1,11]],"date-time":"2024-01-11T00:00:00Z","timestamp":1704931200000},"content-version":"vor","delay-in-days":10,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["ascpt.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Clinical Translational Sci"],"published-print":{"date-parts":[[2024,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Multiple myeloma (MM) remains incurable despite improvements in treatment options. B\u2010cell maturation antigen (BCMA) is predominantly expressed in B\u2010lineage cells and represents a promising new target for MM. Teclistamab (TECVAYLI<jats:sup>TM<\/jats:sup>) is the first T\u2010cell redirecting bispecific antibody approved for patients with MM. Targeting both CD3 receptor complex on T cells and BCMA on myeloma cells, teclistamab leads to T\u2010cell activation and subsequent lysis of BCMA+ cells. The recommended dose of teclistamab is 1.5\u2009mg\/kg subcutaneous weekly after two step\u2010up doses of 0.06 and 0.3\u2009mg\/kg, which was selected after review of safety, efficacy, pharmacokinetic, and pharmacodynamic data. Exposure\u2010response analyses of efficacy and safety data were also used to confirm the teclistamab dose. Teclistamab resulted in a high rate of deep and durable responses (63% overall response, 45.5% complete response or better, with 22\u2009months median duration of response) in patients with triple\u2010exposed relapsed\/refractory MM. Common adverse reactions included cytokine release syndrome, hematologic abnormalities, and infections. Teclistamab is currently being investigated as monotherapy as well as combination therapy across different MM indications.<\/jats:p>","DOI":"10.1111\/cts.13717","type":"journal-article","created":{"date-parts":[[2024,1,12]],"date-time":"2024-01-12T07:20:38Z","timestamp":1705044038000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["Teclistamab: Mechanism of action, clinical, and translational science"],"prefix":"10.1111","volume":"17","author":[{"given":"Yue","family":"Guo","sequence":"first","affiliation":[{"name":"Janssen Research &amp; Development  Spring House Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia A.","family":"Quijano\u00a0Card\u00e9","sequence":"additional","affiliation":[{"name":"Janssen Research &amp; Development  Spring House Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijuan","family":"Kang","sequence":"additional","affiliation":[{"name":"Janssen Research &amp; Development  Spring House Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raluca","family":"Verona","sequence":"additional","affiliation":[{"name":"Janssen Research &amp; Development  Spring House Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnob","family":"Banerjee","sequence":"additional","affiliation":[{"name":"Janssen Research &amp; Development  Spring House Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Kobos","sequence":"additional","affiliation":[{"name":"Janssen Research &amp; Development  Spring House Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Chastain","sequence":"additional","affiliation":[{"name":"Janssen Research &amp; Development  Spring House Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clarissa","family":"Uhlar","sequence":"additional","affiliation":[{"name":"Janssen Research &amp; Development  Spring House Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kodandaram","family":"Pillarisetti","sequence":"additional","affiliation":[{"name":"Janssen Research &amp; Development  Spring House Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret","family":"Doyle","sequence":"additional","affiliation":[{"name":"Janssen Sciences Ireland  Dublin Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Smit","sequence":"additional","affiliation":[{"name":"Janssen Research &amp; Development  Spring House Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nahor","family":"Haddish\u2010Berhane","sequence":"additional","affiliation":[{"name":"Janssen Research &amp; Development  Spring House Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Ouellet","sequence":"additional","affiliation":[{"name":"Janssen Research &amp; Development  Spring House Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,1,11]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-023-00853-3"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-12-2422"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020002393"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11523-022-00893-y"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)01338-6"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2203478"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.yrtph.2017.09.001"},{"key":"e_1_2_10_9_1","unstructured":"Center for Drug Evaluation and Research.NDA\/BLA Multi\u2010disciplinary review and evaluation {BLA 761291} teclistamab. Accessed August 3 2023.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2022\/761291Orig1s000MultidisciplineR.pdf"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.dmpk.2017.05.002"},{"key":"e_1_2_10_11_1","volume-title":"TECVAYLI (Teclistamab\u2010Cqyv) Injection, for Subcutaneous Use [Package Insert]","year":"2022"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11523-023-00989-z"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.13996"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-162709"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.34756"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/psp4.12660"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022007625"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2016.150896"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.8034"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.8011"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.8033"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-162856"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.6004\/jadpro.2023.14.4.4"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2023.2181016"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/cts.12662"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2023.106492"}],"container-title":["Clinical and Translational Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/cts.13717","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,24]],"date-time":"2024-01-24T18:42:07Z","timestamp":1706121727000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/10.1111\/cts.13717"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["10.1111\/cts.13717"],"URL":"https:\/\/doi.org\/10.1111\/cts.13717","archive":["Portico"],"relation":{},"ISSN":["1752-8054","1752-8062"],"issn-type":[{"value":"1752-8054","type":"print"},{"value":"1752-8062","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"2023-08-18","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-12-19","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-01-11","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e13717"}}